Wegovy and Mounjaro are not the same medication. They contain different active ingredients, work through different biological mechanisms, and are FDA-approved for different conditions. That said, both are weekly injectable medications that cause significant weight loss, which is why they’re so often compared. Understanding what sets them apart can help you make sense of which one might be relevant to your situation.
Different Active Ingredients, Different Drug Classes
Wegovy’s active ingredient is semaglutide. It belongs to a class of drugs called GLP-1 receptor agonists, meaning it mimics a single gut hormone (GLP-1) that your body naturally produces after eating. This hormone helps regulate blood sugar, slows digestion, and reduces appetite by signaling fullness to the brain.
Mounjaro’s active ingredient is tirzepatide. It’s a dual-agonist, meaning it mimics two gut hormones instead of one: both GLP-1 and another called GIP. Both of these hormones play roles in blood sugar regulation and metabolism, but activating two pathways simultaneously appears to produce stronger effects on weight and blood sugar than targeting GLP-1 alone. This dual mechanism is the single biggest pharmacological difference between the two drugs.
They’re Approved for Different Conditions
Mounjaro is FDA-approved specifically for type 2 diabetes management. Its weight-loss counterpart, Zepbound (same ingredient, tirzepatide, at weight-management doses), is the version approved for obesity. So if your doctor prescribes Mounjaro, it’s technically for blood sugar control, not weight loss.
Wegovy has a broader set of FDA approvals. It’s indicated for long-term weight reduction in adults and adolescents aged 12 and older with obesity, or in adults with overweight who also have at least one weight-related health condition. Beyond weight loss, Wegovy is also approved to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with established heart disease who have obesity or overweight. It also recently gained approval for a type of fatty liver disease called MASH with moderate to advanced scarring.
That cardiovascular approval is significant. In a large clinical trial called SELECT, semaglutide reduced the risk of major cardiovascular events by 20% compared to placebo in people with heart disease and overweight or obesity. Tirzepatide does not yet have this cardiovascular indication.
How Weight Loss Results Compare
Both medications produce substantial weight loss, but tirzepatide has shown an edge in clinical trials. In the STEP 1 trial, people taking Wegovy (semaglutide 2.4 mg) lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. For someone starting at 250 pounds, that translates to roughly 37 pounds.
In the SURMOUNT-1 trial, tirzepatide at its three dose levels produced even greater results over a similar timeframe of 72 weeks. The 5 mg dose led to 15% body weight loss, the 10 mg dose to 19.5%, and the highest 15 mg dose to 20.9%. The placebo group lost 3.1%. At the highest dose, a person starting at 250 pounds would lose roughly 52 pounds. These are averages, and individual results vary considerably, but the pattern across trials is consistent: tirzepatide’s dual-hormone approach tends to produce more weight loss at the higher doses.
One important caveat: Wegovy appears to produce less weight loss in people who have type 2 diabetes compared to those without it. This is worth keeping in mind if you’re evaluating these medications for weight management alongside diabetes care.
Dosing and How You Take Them
Both medications are once-weekly injections that start at a low dose and gradually increase over several months to reduce side effects. This ramp-up period is called titration.
Wegovy starts at 0.25 mg per week and increases in steps until reaching the maintenance dose of 2.4 mg. Mounjaro starts at 2.5 mg per week and increases in 2.5 mg increments every four weeks, with a maintenance dose ranging from 5 mg to 15 mg depending on how you respond and what your doctor recommends. The flexible upper range with Mounjaro means your provider can adjust your dose based on your results and tolerability.
Wegovy also recently became available as an oral tablet for some indications, though the injectable form remains the most widely used version.
Side Effects Are Similar but Not Identical
The most common side effects of both medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be worst during the titration period when your dose is increasing and often improve over time as your body adjusts. The gradual dose escalation schedule for both drugs exists specifically to minimize these effects.
Because both drugs act on the GLP-1 pathway, the overall side effect profiles overlap substantially. However, the dual-agonist nature of tirzepatide means its interaction with the body is not identical to semaglutide’s, and individual tolerance can differ. Some people who struggle with one medication do fine on the other, which is one reason providers sometimes switch patients between them.
Cost Without Insurance
Both medications carry high list prices. Without insurance, Mounjaro runs approximately $1,094 per month, while Wegovy costs around $1,326 per month. Actual out-of-pocket costs vary widely depending on your insurance plan, employer benefits, and whether you qualify for manufacturer savings programs. Both companies offer discount cards for eligible patients, but coverage remains one of the biggest practical barriers for people prescribed either drug.
Which One Is “Better”?
There’s no universal answer. Tirzepatide (Mounjaro/Zepbound) has produced greater average weight loss in clinical trials, which makes it appealing for people whose primary goal is maximum weight reduction. Semaglutide (Wegovy) has the proven cardiovascular benefit and broader FDA-approved indications, making it a stronger choice for people with heart disease or those whose provider wants a medication with more long-term outcomes data. Your insurance coverage, the specific condition being treated, and how your body responds to each drug all factor into the decision.